High Rates of Intestinal Colonization with Extended-Spectrum Lactamase-Producing Enterobacteriaceae among Healthy Individuals

Journal of Investigative Medicine

Volumn 59, Issue 8, 2011, Pages 1284-1286

  Abdul Rahman, Eiman Mohammed ^a   El Sherif, Rasha Hamed ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

extended spectrum lactamases; MacConkey selective agars

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADULT; AGED; ARTICLE; BACTERIAL COUNT; BIOSYNTHESIS; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYMOLOGY; ESCHERICHIA COLI; FECES; HEALTH; HUMAN; INTESTINE; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BETA-LACTAMASES; COLONY COUNT, MICROBIAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FECES; HEALTH; HUMANS; INTESTINES; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; YOUNG ADULT;

EID: 84857989724     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318238748e     Document Type: Article

References (22)

1. Moland SE, Black JA, Ourada J et al. Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 US hospitals. Antimicrob Agents Chemother. 2002; 46: 3837–3842.
2. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001; 14: 933–951.
3. Rodriguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004; 42: 1089–1094.
4. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2004; 54: 735–743.
5. Helal SF, Wassef MA, Behiry IK et al. Detection of extended-spectrum beta lactamase (ESBL) in health care associated infections with Klebsiella species expressing SHV1 and/or TEM gene. Arab J Lab Med. 2011; 37 (2): 355–364.
6. Performance Standards for Antimicrobial Susceptibility Testing: 10th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2009 (M100–S15).
7. Schreckenberger PC, Janda JM, Wong JD et al. Algorism for identification of aerobic gram negative bacilli. In: Murray PR, Baron EJ, Jorgensen JH et al., eds.Manual of Clinical Microbiology. 9th ed. Washington, DC: ASM Press; 2009; 26: 438–441.
8. High rates of intestinal colonization with extended-spectrum lactamase-producing Enterobacteriaceae in patients at a tertiary-care hospital in Israel. Presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases, April 10-13, 2010, Vienna, Austria. Abstract P713.
9. Kader AA, Kamath KA. Faecal carriage of extended-spectrum β-lactamase-producing bacteria in the community. East Mediterr Health J. 2009; 15 (6): 1365.
10. Abdul Rahman EM, El-Sherif RH. High prevalence of antimicrobial resistance among bacterial pathogens of community-acquired urinary tract infection: impact on empiric therapy. Egypt J Lab Med. 2011. In press.
11. Kader AA, Kumar A. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other Gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi Med J. 2005; 26 (6): 956–959.
12. Kader AA, Kumar A. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Ann Saudi Med. 2005; 25 (3): 239–242.
13. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2004; 54: 735–743.
14. Cormican M, Morris D, Corbett-Feeeney G et al. Extended-spectrum β-lactamase production and fluoroquinolone resistance in pathogens associated with community urinary tract infection. Diagn Microbiol Infect Dis. 1998; 32: 317–319.
15. Lucet JC, Chevret S, Decré D et al. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit epidemiology and risk factors for acquisition. Clin Infect Dis. 1996; 22: 430–436.
16. Moland SE, Black JA, Ourada J et al. Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother. 2002; 46: 3837–3842.
17. Levin BR. Minimizing potential resistance: a population dynamics view. Clin Infect Dis. 2001; 33 (suppl 3): S161–S169.
18. Livermore DM. beta-Lactamase-mediated resistance and opportunities for its control. J Antimicrob Agents. 1998; 41: 25–41.
19. Bosi C, Bosi C, Davin-Regli A et al. Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol. 1999; 37: 2165–2169.
20. Bonten MJ, Slaughter S, Ambergen AW et al. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med. 1998; 158: 1127–1132.
21. Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum β-lactamase producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004; 23: 163–167.
22. Heseltine P. Has resistance spread to the community? Clin Microbiol Infect. 2000; 6: 11–16.